3SBio Outlines Plans For $540m IPO Spoils
This article was originally published in PharmAsia News
Executive Summary
China biotech firm 3SBio, which delisted from Nasdaq in 2013, has raised HKD$4.17bn ($540 million) through an initial public offering on the Hong Kong stock exchange, which it will use mainly to expand its product portfolio and pipeline.